Ignite Creation Date:
2024-05-06 @ 6:24 PM
Last Modification Date:
2024-10-26 @ 2:47 PM
Study NCT ID:
NCT05646862
Status:
RECRUITING
Last Update Posted:
2024-06-21
First Post:
2022-12-02
Brief Title:
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive HER2-Negative PIK3CA Mutated Locally Advanced or Metastatic Breast Cancer Post CDK46i and Endocrine Combination Therapy
Sponsor:
Organization:
Hoffmann-La Roche